Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab’s Promising Data (NASDAQ:ZYME)
Caiaimage/Martin Barraud/iStock via Getty Images Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biotechnology company focused on developing innovative therapies for challenging to treat cancers and other serious conditions. ZYME leverages proprietary platforms concentrated on Multispecific Antibody Therapeutics and Antibody-Drug Conjugate Technologies. These platforms drive the creation of treatments to support a dynamic pipeline of drug candidates,…